Condition
Selected Advanced Solid Tumors
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Active Not Recruiting1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07812805Phase 1RecruitingPrimary
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
NCT03530397Phase 1Active Not RecruitingPrimary
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT06877533Phase 1TerminatedPrimary
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
Showing all 3 trials